HomeCompareGUOSF vs ABBV

GUOSF vs ABBV: Dividend Comparison 2026

GUOSF yields 3.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GUOSF wins by $414.28M in total portfolio value· pulled ahead in Year 3
10 years
GUOSF
GUOSF
● Live price
3.00%
Share price
$2.00
Annual div
$0.06
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$414.38M
Annual income
$389,434,269.58
Full GUOSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GUOSF vs ABBV

📍 GUOSF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGUOSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GUOSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GUOSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GUOSF
Annual income on $10K today (after 15% tax)
$254.90/yr
After 10yr DRIP, annual income (after tax)
$331,019,129.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GUOSF beats the other by $330,998,073.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GUOSF + ABBV for your $10,000?

GUOSF: 50%ABBV: 50%
100% ABBV50/50100% GUOSF
Portfolio after 10yr
$207.24M
Annual income
$194,729,520.67/yr
Blended yield
93.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GUOSF
No analyst data
Altman Z
0.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GUOSF buys
0
ABBV buys
0
No recent congressional trades found for GUOSF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGUOSFABBV
Forward yield3.00%3.06%
Annual dividend / share$0.06$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$414.38M$102.3K
Annual income after 10y$389,434,269.58$24,771.77
Total dividends collected$412.53M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GUOSF vs ABBV ($10,000, DRIP)

YearGUOSF PortfolioGUOSF Income/yrABBV PortfolioABBV Income/yrGap
1$11,300$599.77$11,550$430.00$250.00ABBV
2$13,358$1,266.77$13,472$627.96$114.00ABBV
3← crossover$17,092$2,798.98$15,906$926.08+$1.2KGUOSF
4$24,982$6,694.24$19,071$1,382.55+$5.9KGUOSF
5$45,020$18,289.28$23,302$2,095.81+$21.7KGUOSF
6$109,777$61,605.57$29,150$3,237.93+$80.6KGUOSF
7$398,245$280,783.07$37,536$5,121.41+$360.7KGUOSF
8$2,330,070$1,903,947.78$50,079$8,338.38+$2.28MGUOSF
9$23,315,066$20,821,891.69$69,753$14,065.80+$23.25MGUOSF
10$414,381,390$389,434,269.58$102,337$24,771.77+$414.28MGUOSF

GUOSF vs ABBV: Complete Analysis 2026

GUOSFStock

Guotai Junan Securities Co., Ltd. provides various financial services for individuals and institutional clients in Mainland China, Hong Kong, and internationally. It operates through Wealth Management Business, Investment Banking Business, Institutional and Trading Business, Investment Management Business, and International Business segments. The company offers securities and futures brokerage, financial products, investment advisory, margin financing and securities lending, securities repurchase, and stock pledging and other services; listing sponsorship, equity underwriting, debt underwriting, structured debt financing, M&A financial advisory, and diversified corporate solutions to corporate and governmental clients; institutional brokerage, trading, investment and equity investment, seat leasing, custody and outsourcing, QFII, and other services; and investment transactions in stocks, fixed income, foreign exchange, and commodities and their derivative financial instruments, as well as integrated financial solutions for clients' investment, financing, and risk management. It also provides asset management and fund management services; and brokerage, corporate finance, asset management, and loans and financing services, as well as financial products, and market making and investment services. In addition, the company offers real estate and property management, warehouse service, corporate management consulting, venture capital investment and management, investment management, industrial investment, and investment consulting services. The company was founded in 1992 and is based in Shanghai, China.

Full GUOSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GUOSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GUOSF vs SCHDGUOSF vs JEPIGUOSF vs OGUOSF vs KOGUOSF vs MAINGUOSF vs JNJGUOSF vs MRKGUOSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.